Prezcobix and Evotaz: Two New HIV Fixed Dose Combinations Approved this Week
January 29, 2015
Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved PREZCOBIX™ (darunavir 800 mg/cobicistat 150 mg) tablets, an HIV-1 protease inhibitor combined with a CYP3A4 inhibitor, for the treatment of human immunodefic iency virus (HIV-1) in combination with other antiretroviral agents for (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - January 30, 2015 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
Prezcobix and Evotaz: Two New HIV Fixed Dose Combinations Approved this Week
January 29, 2015
Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved PREZCOBIX™ (darunavir 800 mg/cobicistat 150 mg) tablets, an HIV-1 protease inhibitor combined with a CYP3A4 inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral agents for (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - January 29, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
Groundbreaking HIV vaccine's effects were real – and could be made to work better
Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P). They showed evidence of stronger antibody responses, and in-depth analysis of these responses shows that by further developing a similar vaccine it may be possible to push the immune system into (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - November 15, 2014 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
Prevalence and risk factors of sleep disturbances in a large HIV-infected adult population.
Authors
Allavena C1, Guimard T2, Billaud E3, de la Tullaye S4, Reliquet V1, Pineau S3, Hüe H3, Supiot C1,Chennebault JM5, Michau C6, Hitoto H7, Vatan R8, Raffi F1.
Author information
Journa l
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19576. doi: 10.7448/IAS.17.4.19576. eCollection 2014.
Affiliation (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - November 15, 2014 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
Groundbreaking HIV vaccine's effects were real – and could be made to work better
Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P). They showed evidence of stronger antibody responses, and in-depth analysis of these responses sh ows that by further developing a similar vaccine it may be possible to push the immune system into (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - November 15, 2014 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
Cost Effectiveness of Current HIV Cure Approaches
We examined efficacy, toxicity, relapse, cost, and quality-of-life thresholds of hypothetical HIV cure interventions that would make them cost-effective compared to life-long antiretroviral therapy (ART).
Methods
We used a computer simulation model to assess three HIV cure strategies: Gene Therapy, (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - November 15, 2014 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
Prevalence and risk factors of sleep disturbances in a large HIV-infected adult population.
Authors
Allavena C1, Guimard T2, Billaud E3, de la Tullaye S4, Reliquet V1, Pineau S3, Hüe H3, Supiot C1,Chennebault JM5, Michau C6, Hitoto H7, Vatan R8, Raffi F1.
Author information
Journal
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19576. doi: 10.7448/IAS.17.4.19576. eCollection 2014.
Affiliation (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - November 14, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
Groundbreaking HIV vaccine's effects were real – and could be made to work better
Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P). They showed evidence of stronger antibody responses, and in-depth analysis of these responses shows that by further developing a similar vaccine it may be possible to push the immune system into (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - November 14, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
Cost Effectiveness of Current HIV Cure Approaches
We examined efficacy, toxicity, relapse, cost, and quality-of-life thresholds of hypothetical HIV cure interventions that would make them cost-effective compared to life-long antiretroviral therapy (ART).
Methods
We used a computer simulation model to assess three HIV cure strategies: Gene Therapy, (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - November 14, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
Ibalizumab: First HIV Drug to Get Orphan Drug Status for Salvage Patients
Shares of TaiMed Biologics Inc, which manufactures drugs to treat AIDS, soared 12.93 percent yesterday after its new TMB-355 drug for intravenous injection was granted orphan drug status in the US.
The company’s shares closed at NT$151.2 yesterday, outperforming the over-the-counter benchmark index, which ended up 0.56 percent.
The granting of orphan status could shorten the time it takes for (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 22, 2014 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
Ibalizumab: First HIV Drug to Get Orphan Drug Status for Salvage Patients
Shares of TaiMed Biologics Inc, which manufactures drugs to treat AIDS, soared 12.93 percent yesterday after its new TMB-355 drug for intravenous injection was granted orphan drug status in the US.
The company’s shares closed at NT$151.2 yesterday, outperforming the over-the-counter benchmark index, which ended up 0.56 percent.
The granting of orphan status could shorten the time it takes for (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 21, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
Demystifying HIV Pre-Exposure Prophylaxis
Pre-Exposure
Prophylaxis or PrEP is an HIV prevention strategy where an HIV negative person
takes a daily pill to reduce their risk of contracting HIV. It's important to
note that PrEP is not the same as PEP or Post-Exposure Prophylaxis, which HIV
treatment given to individuals within 72 hours after exposure to HIV to prevent
infection from taking hold.
The only currently
approved (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 19, 2014 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
Video: Three PrEP Myths Busted (One Pill Per Day to Prevent HIV)
(Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 17, 2014 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
